Olanzapine for the Prevention of Postoperative Nausea and Vomiting
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three
prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for
PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic
represents a new use of an antipsychotic drug.